Lung highlights from ESMO 2018

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer

The standard of care and progress so far with PARP inhibitors for ovarian cancer

KEYNOTE022: Triplet therapy for BRAF melanoma

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

ESMO 2018: Melanoma highlights

IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

ESMO 2018: Highlights

IMpassion 130 trial results: Immunotherapy for metastatic breast cancer